Literature DB >> 31481635

β2-Adrenergic genotypes and risk of severe exacerbations in COPD: a prospective cohort study.

Truls Sylvan Ingebrigtsen1,2,3, Jørgen Vestbo4,5, Line Rode2,6, Jacob Louis Marott2,3, Peter Lange1,2,3,7, Børge G Nordestgaard8,3,6.   

Abstract

BACKGROUND: Individual susceptibility to exacerbations in chronic obstructive pulmonary disease (COPD) is likely influenced by genetic factors; however, most such variance is unexplained. We hypothesised that β2-adrenergic receptor genotypes, Gly16Arg (rs1042713, c.46G>A) and Gln27Glu (rs1042714, c.79C>G) influence risk of severe exacerbations in COPD.
METHODS: Among 96 762 individuals in the Copenhagen General Population Study, we identified 5262 with COPD (forced expiratory volume in one second divided by forced vital capacity, FEV1/FVC, below 0.7, FEV1 less than 80% of predicted value, age above 40 years and no asthma) who had genotyping performed. Severe exacerbations were defined as acute admissions due to COPD during 5 years of follow-up (mean 3.4 years). 923 individuals with COPD diagnosed similarly in the Copenhagen City Heart Study (CCHS) were used for replication analyses.
RESULTS: We recorded 461 severe exacerbations in 5262 subjects. The HRs for severe exacerbations were 1.62 (95% CI 1.30 to 2.03, p=0.00002) for 16Gly/Arg heterozygotes and 1.41 (1.04 to 1.91, p=0.03) for 16Arg homozygotes, compared with 16Gly homozygotes. HRs were 1.35 (1.03 to 1.76, p=0.03) for 27Gln/Glu heterozygotes and 1.49 (1.12 to 1.98, p=0.006) for 27Gln homozygotes, compared with 27Glu homozygotes. Similar trends were observed in the CCHS. Among 27Gln homozygotes only, HRs were 5.20 (1.81 to 14.9, p=0.002) for 16Gly/Arg heterozygotes and 4.03 (1.40 to 11.6, p=0.01) for 16Arg homozygotes, compared with 16Gly homozygotes.
CONCLUSION: Common β2-adrenergic receptor genotypes influence risk of severe exacerbations in COPD, potentially mainly by genetic influence of the 16Arg allele in rs1042713. © Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  COPD; adrenoreceptor polymorphisms; precision medicine

Mesh:

Substances:

Year:  2019        PMID: 31481635     DOI: 10.1136/thoraxjnl-2018-212340

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  4 in total

1.  β2 adrenergic receptor polymorphisms and COPD exacerbations: a complicated story.

Authors:  Wassim W Labaki; MeiLan K Han
Journal:  Thorax       Date:  2019-09-03       Impact factor: 9.139

2.  β2-Adrenergic Receptor (ADRB2) Gene Polymorphisms and Risk of COPD Exacerbations: The Rotterdam Study.

Authors:  Leila Karimi; Lies Lahousse; Mohsen Ghanbari; Natalie Terzikhan; André G Uitterlinden; Johan van der Lei; Guy G Brusselle; Bruno H Stricker; Katia M C Verhamme
Journal:  J Clin Med       Date:  2019-11-01       Impact factor: 4.241

3.  Association between beta-2 adrenergic receptor variants and clinical outcomes in children and adolescents with acute asthma.

Authors:  Fábio Pereira Muchão; Andréa Vieira de Souza; Juliana Miguita E Souza; Luiz Vicente Ribeiro Ferreira da Silva Filho
Journal:  Einstein (Sao Paulo)       Date:  2022-03-25

4.  Association of matrix metalloproteinase-12 polymorphisms with chronic obstructive pulmonary disease risk: A protocol for systematic review and meta analysis.

Authors:  Hongjing Yang; Chuantao Zhang; Jianying Wu; Wei Xiao; Xiaohong Xie; Zhu Zeng; Keling Chen; Wujun Wang; Xing An; Wenjun Tang; Qingsong Huang
Journal:  Medicine (Baltimore)       Date:  2020-07-31       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.